Advanced Biomed Inc. Announces 120?Case Feasibility Study with Chi?Mei Medical Center to Validate A+PerfusC(TM) - Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
MWN-AI** Summary
Advanced Biomed Inc. (Nasdaq: ADVB), a biotech firm specializing in innovative biomedical solutions for precision medicine and advanced diagnostics, has announced a partnership with Chi-Mei Medical Center to conduct a significant 120-case feasibility study. This study aims to evaluate the A+PerfusC™ platform, a perfusion-based 3D cell culture system designed to replicate human physiological conditions in vitro. This initiative, which received Institutional Review Board approval, began case collection in early February 2026, with interim data expected by mid-2026 and full results anticipated by the end of the year.
The A+PerfusC platform allows for high-viability circulating tumor cells (CTCs) to be isolated and cultured, addressing major limitations of traditional two-dimensional and animal models. By offering a functional, patient-derived testing mechanism, the system seeks to provide oncologists with more precise drug sensitivity data derived from minimally invasive liquid biopsies. This could significantly impact treatment decision-making, potentially speeding up the process and decreasing patient exposure to ineffective therapies.
Dr. Yi Lu, CEO of Advanced Biomed, emphasized that the study is an essential step toward verifying the platform's real-world predictive value in oncology, shifting from genomic-based inference to individualized functional testing. The collaboration will not only enhance clinical practice but also tackle ethical concerns associated with animal testing by employing patient-derived tumor spheroids for high-throughput screening.
Both Advanced Biomed and Chi-Mei Medical Center will share rights to intellectual property stemming from their collaboration, positioning the feasibility study as a precursor to larger clinical validation trials. This project highlights Advanced Biomed’s commitment to pioneering methodologies that improve cancer treatment selection through cutting-edge technology.
MWN-AI** Analysis
Advanced Biomed Inc. (Nasdaq: ADVB) recently announced a significant collaboration with Chi-Mei Medical Center to conduct a 120-case feasibility study on its A+PerfusC™ platform. This compact incubator system aims to replicate human physiological conditions for in vitro drug testing, potentially transforming precision medicine and oncology therapy selection.
The strategic partnership signals a pivotal moment for Advanced Biomed, especially after the commercial launch of the A+PerfusC platform in September 2025. The upcoming interim data expected in May–June 2026 and full completion slated for year-end 2026 will be crucial. Investors should closely monitor these developments, as successful outcomes could validate the platform's predictive capabilities and enhance its appeal as a clinical decision support tool.
Advanced Biomed’s innovative approach addresses the limitations of traditional preclinical models, offering a patient-specific, high-throughput solution through label-free microfluidic technology. Given the ongoing emphasis on personalized medicine, the potential market for A+PerfusC is substantial. If the feasibility study demonstrates a strong correlation between the predicted drug sensitivities and actual patient outcomes, it could catalyze further studies and regulatory approvals, enhancing market demand.
From a market perspective, shares of Advanced Biomed could see increased volatility in the lead-up to the release of interim and final results. Investors should consider accumulating positions ahead of these milestones, particularly if the company can demonstrate robust early data that suggest a favorable trend for clinical validation. However, it is prudent to remain cautious of the inherent risks associated with biotech stocks, particularly those relying on clinical trial outcomes.
In summary, Advanced Biomed Inc. presents compelling potential, but investors should prepare for the risks and uncertainties associated with the clinical study landscape while keeping a close eye on crucial upcoming data releases.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Tainan, Taiwan, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced the Company has entered into a clinical research collaboration agreement (the “Agreement”) with Chi?Mei Medical Center to initiate a 120?case feasibility study designed to evaluate the predictive accuracy of the Company’s A+PerfusC™, a perfusion-based 3D cell culture in a compact incubator designed to replicate human physiological conditions in vitro.
The feasibility study is a non?interventional clinical research project that received Institutional Review Board approval. Case collection has begun in early February 2026 at Chi?Mei Medical Center, with interim comparative data expected in May–June 2026 and full study completion targeted by year?end 2026. The study will compare ex?vivo drug sensitivity results generated by the A+PerfusC platform from circulating tumor cells obtained via liquid biopsy with actual patient clinical outcomes to assess correlation and predictive performance. It follows the Company’s September 2025 commercial launch of the A+PerfusC integrated perfusion 3D cell culture platform and represents an additional avenue to convert the system’s laboratory strengths into evidence that can be used in clinical practice.
This collaboration is significant because it seeks to address a central limitation of current preclinical and guideline?driven approaches to oncology treatment selection. Two?dimensional cell culture models and xenograft animal models frequently fail to recapitulate the complex, patient?specific biology of human tumors and are constrained by low throughput and long turnaround times. By contrast, the A+PerfusC platform isolates high?viability circulating tumor cells using label?free microfluidic technology and grows them in automated 3D culture arrays that enable parallel testing of multiple drugs and combinations. This functional, patient-derived testing approach aims to shorten the time to an evidence?based treatment decision, reduce exposure to ineffective therapies and their toxicities, and provide clinicians with a practical tool to prioritize therapies most likely to benefit an individual patient.
Beyond direct patient impact, the platform also addresses practical and ethical constraints associated with animal?based models. Replacing large cohorts of mice with high?density arrays of patient?derived tumor spheroids enables high?throughput screening that is not feasible with xenografts, while Advanced Biomed’s automated A+PerfusCTM system is intended to reduce labor intensity and scale functional testing to clinically actionable timeframes. The Company expects the feasibility study’s results to inform the design of subsequent, larger clinical validation studies and to support its use as a predictive tool for treatment response and Clinical Decision Support (CDS), pending favorable outcomes and regulatory review.
“We believe the A+PerfusC platform can materially improve how oncologists select therapies by delivering patient?specific, functional drug sensitivity data derived from a minimally invasive liquid biopsy,” said Dr. Yi Lu, Chief Executive Officer of Advanced Biomed. “This feasibility study with Chi?Mei Medical Center is a critical step toward demonstrating the platform’s real?world predictive value and advancing precision oncology beyond genomic inference to functional, individualized testing.”
Advanced Biomed and Chi?Mei Medical Center will jointly conduct the non?commercial clinical research and collaborate on subsequent commercial development. Under the Agreement, both parties will share rights to project-related intellectual property and research outcomes.
About Advanced Biomed Inc.
Advanced Biomed Inc. is a Nevada corporation specializing in innovative biomedical technologies for cancer detection and precision medicine.
Operating through the subsidiary in Taiwan, the Company has developed a proprietary microfluidic platform that integrates semiconductor and biotechnology to enable advanced circulating tumor cell (CTC) detection, enrichment, and analysis. Its portfolio includes devices, biochips, and designed for cancer screening, diagnosis, treatment selection, and prognosis assessment, with regulatory clearances in progress in Taiwan and plans for future global expansion.
For more information, please visit: www.advanbiomed.com.
Forward?Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the documents filed with the United States Securities and Exchange Commission (the “SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
Advanced Biomed Inc.
Steven I-Fang Cheng
Email: info@advbiomedicine.com
invest@advbiomedicine.com
FAQ**
How does Advanced Biomed Inc. (Nasdaq: ADVB) plan to utilize the data from the feasibility study at Chi?Mei Medical Center to enhance the predictive accuracy of the A+PerfusC platform in clinical practice?
What are the expected regulatory challenges Advanced Biomed Inc. (ADVB) may face in the market introduction of the A+PerfusC platform following the feasibility study's findings?
Can you elaborate on how Advanced Biomed Inc. (Nasdaq: ADVB) anticipates the A+PerfusC platform will improve the current oncological treatment selection process compared to traditional methods?
What strategic partnerships or collaborations does Advanced Biomed Inc. (ADVB) foresee as essential for further commercialization of the A+PerfusC technology post the clinical feasibility study?
**MWN-AI FAQ is based on asking OpenAI questions about Advanced Biomed Inc. (NASDAQ: ADVB).
NASDAQ: ADVB
ADVB Trading
21.02% G/L:
$5.0225 Last:
46,696 Volume:
$4.34 Open:
